Ritu Salani, MD, MBA, UCLA Health, Los Angeles, CA, discusses the implications of phase three clinical trials for patients with endometrial cancer with deficient mismatch repair (dMMR). Checkpoint inhibition has shown clear efficacy in this population. However, there are ongoing debates regarding the use of immunotherapy in proficient mismatch repair (pMMR) patients, with conflicting evidence on progression-free survival (PFS) benefits. Exploratory subgroup analyses are underway to identify potential responders. The shift towards immunotherapy as a frontline treatment for dMMR patients raises questions about the sequencing of therapies, particularly in the second-line. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
